Latest Conference Articles

FSGS recurrence threatens transplant success, yet clinicians still lack reliable predictors, mechanisms, and effective prevention strategies.

New late-breaking phase 3 data suggest zasocitinib may help reshape the oral treatment landscape for moderate-to-severe plaque psoriasis.

Fearon discusses results from the ALL-RISE trial, which demonstrated the FFRangio’s efficacy in assessing lesions for patients with coronary artery disease.

Results of the MOMENTUM trial suggest the prevalence of hypercortisolism in resistant hypertension could be greater than previous estimates have indicated.

Although not statistically significant, the reduction represents a potential new pathway for treating patients with STEMI.

In this segment of his interview, Eichenfield highlights the safety and tolerability of roflumilast cream for children with atopic dermatitis in INTEGUMENT-OLE.

Hypertension drives millions of preventable deaths, yet control lags globally. The HEARTS framework offers practical, scalable solutions to close this gap.

The IMMpactful direct comparison provides prospective data in a moderate psoriasis population that previous MAICs could not fully capture.

Vlado Perkovic, MBBS, PhD, discusses APPLAUSE-IgAN data showing iptacopan reduced eGFR decline and lowered kidney event risk in IgA nephropathy.

CAR-T therapy shows potential for deep, durable remission in lupus nephritis, but questions remain on safety, durability, and patient selection.

A subgroup analysis of VESALIUS-CV suggests evolocumab could have a role in prevention of primary events in some high-risk patients.

New data from the KARDINAL trial at ACC.26 provides insight, but raises questions regarding tonlamarsen and hypertension.

Sarma discusses the ongoing movement to highlight the different cardiovascular risks facing women, particularly during the most turbulent periods of life.

These 52-week, phase 3 data on icotrokinra, presented at AAD, highlight the drug's efficacy and safety among adults with moderate to severe plaque psoriasis.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Rosmarin discussed new late-breaking data from ADVANCE-AA at AAD 2026.

This late-breaking, phase 2 data highlights nemolizumab's clinically meaningful benefits for children with moderate-to-severe atopic dermatitis.

HI-PEITHO concluded use of ultrasound-facilitated catheter-directed fibrinolysis improves pulmonary embolism outcomes.

Soung discussed how new 52-week data support icotrokinra's recent FDA approval, marketed as Icotyde.

REMODEL offers new mechanistic insights into semaglutide, highlighting microvascular and endothelial effects that help explain its kidney and cardiovascular benefits.

KDIGO updates in IgA nephropathy highlight lower proteinuria targets, improved risk tools, and an expanding landscape of targeted and combination therapies.

This interview at AAD 2026 highlights Nguyen's views on the biggest drivers of patient dissatisfaction in dermatology practice settings.

Tildrakizumab is US FDA-approved for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

This interview at AAD 2026 highlights tips for clinicians in dermatology practices who want to improve patient communication and satisfaction.

A post-hoc analysis of phase 3 trials found tapinarof cream 1% produced skin clearance and itch relief as early as week 1 in patients aged 2 years and older.

Janiene Luke, MD, co-chair of the Skin of Color Society (SOCS) Scientific Symposium, speaks about complex cases in dermatology and other topics covered at the meeting.

Temitayo Ogunleye, MD, co-chair of the Skin of Color Society Scientific Symposium, speaks with HCPLive about the meeting's guiding theme and topics.